149 related articles for article (PubMed ID: 12181240)
1. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.
Ducreux M; Rougier P; Pignon JP; Douillard JY; Seitz JF; Bugat R; Bosset JF; Merouche Y; Raoul JL; Ychou M; Adenis A; Berthault-Cvitkovic F; Luboinski M;
Ann Oncol; 2002 Aug; 13(8):1185-91. PubMed ID: 12181240
[TBL] [Abstract][Full Text] [Related]
2. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer.
Hansen RM; Ryan L; Anderson T; Krzywda B; Quebbeman E; Benson A; Haller DG; Tormey DC
J Natl Cancer Inst; 1996 May; 88(10):668-74. PubMed ID: 8627643
[TBL] [Abstract][Full Text] [Related]
3. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Kim NK; Park YS; Heo DS; Suh C; Kim SY; Park KC; Kang YK; Shin DB; Kim HT; Kim HJ
Cancer; 1993 Jun; 71(12):3813-8. PubMed ID: 8508349
[TBL] [Abstract][Full Text] [Related]
4. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
[TBL] [Abstract][Full Text] [Related]
5. Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial.
Wagener DJ; Wils JA; Kok TC; Planting A; Couvreur ML; Baron B
Eur J Cancer; 2002 Mar; 38(5):648-53. PubMed ID: 11916546
[TBL] [Abstract][Full Text] [Related]
6. Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).
Duffour J; Bouché O; Rougier P; Milan C; Bedenne L; Seitz JF; Buecher B; Legoux JL; Ducreux M; Vetter D; Raoul JL; François E; Ychou M
Anticancer Res; 2006; 26(5B):3877-83. PubMed ID: 17094417
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma.
André T; Lotz JP; Bouleuc C; Azzouzi K; Houry S; Hannoun L; See J; Esteso A; Avenin D; Izrael V
Ann Oncol; 1996 Feb; 7(2):173-8. PubMed ID: 8777174
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
[TBL] [Abstract][Full Text] [Related]
9. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
Knaebel HP; Märten A; Schmidt J; Hoffmann K; Seiler C; Lindel K; Schmitz-Winnenthal H; Fritz S; Herrmann T; Goldschmidt H; Krempien R; Mansmann U; Debus J; Diehl V; Büchler MW
BMC Cancer; 2005 Apr; 5():37. PubMed ID: 15826316
[TBL] [Abstract][Full Text] [Related]
11. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma.
Nicolson M; Webb A; Cunningham D; Norman A; O'Brien M; Hill A; Hickish T
Ann Oncol; 1995 Oct; 6(8):801-4. PubMed ID: 8589018
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
Ohtsu A; Shimada Y; Shirao K; Boku N; Hyodo I; Saito H; Yamamichi N; Miyata Y; Ikeda N; Yamamoto S; Fukuda H; Yoshida S;
J Clin Oncol; 2003 Jan; 21(1):54-9. PubMed ID: 12506170
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.
Sparano JA; Lipsitz S; Wadler S; Hansen R; Bushunow PW; Kirkwood J; Flynn PJ; Dutcher JP; Benson AB
Am J Clin Oncol; 1996 Dec; 19(6):546-51. PubMed ID: 8931668
[TBL] [Abstract][Full Text] [Related]
15. [5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer].
Taïeb J; Lecomte T; Ezenfis J; Artru P; Mitry E; Boige V; Clavero-Fabri MC; Vaillant JN; Rougier P; Ducreux M
Gastroenterol Clin Biol; 2002; 26(6-7):605-9. PubMed ID: 12193860
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study.
Ahmed S; Vaitkevicius VK; Zalupski MM; Du W; Arlauskas P; Gordon C; Kellogg C; Shields AF
Am J Clin Oncol; 2000 Aug; 23(4):420-4. PubMed ID: 10955876
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Isikdogan A
Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.
Ducreux M; Mitry E; Ould-Kaci M; Boige V; Seitz JF; Bugat R; Breau JL; Bouché O; Etienne PL; Tigaud JM; Morvan F; Cvitkovic E; Rougier P
Ann Oncol; 2004 Mar; 15(3):467-73. PubMed ID: 14998850
[TBL] [Abstract][Full Text] [Related]
20. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.
Maisey N; Chau I; Cunningham D; Norman A; Seymour M; Hickish T; Iveson T; O'Brien M; Tebbutt N; Harrington A; Hill M
J Clin Oncol; 2002 Jul; 20(14):3130-6. PubMed ID: 12118027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
